• Immunotherapy, Novel Therapies, and Shared Decision-Making in Advanced Endometrial Cancer

  • Sep 25 2024
  • Length: 25 mins
  • Podcast

Immunotherapy, Novel Therapies, and Shared Decision-Making in Advanced Endometrial Cancer

  • Summary

  • Drs Ursula A. Matulonis and Mansoor Mirza discuss immunotherapy trials, novel therapies such as CDK4/6 inhibitors and antibody-drug conjugates, and shared decision-making.

    Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999852. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

    Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972026/

    Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972022/

    Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial https://pubmed.ncbi.nlm.nih.gov/37864337/

    Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209) https://pubmed.ncbi.nlm.nih.gov/33078978/

    Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/37669480/

    Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://pubmed.ncbi.nlm.nih.gov/37870536/

    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Immunotherapy, Novel Therapies, and Shared Decision-Making in Advanced Endometrial Cancer

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.